• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks

    Hemispherx Reports 2018 Third Quarter and First Nine Months Financial Results

    Gabrielle Lakusta
    Nov. 15, 2018 09:11AM PST
    Pharmaceutical Investing

    Hemispherx Biopharma (NYSE:HEB) announces financial results for the three and nine months ended September 30, 2018, and provides a business update. As quoted in the press release: Research and development manufacturing-related expenses for the third quarter of 2018 were $1.595 million, a 103% increase compared with $0.787 million for the third quarter of 2017.  The …

    Hemispherx Biopharma (NYSE:HEB) announces financial results for the three and nine months ended September 30, 2018, and provides a business update.

    As quoted in the press release:

    Research and development manufacturing-related expenses for the third quarter of 2018 were $1.595 million, a 103% increase compared with $0.787 million for the third quarter of 2017.  The increase was due to the manufacture of 7,907 Ampligen vials and to the initial costs for the production of polymers.

    General and administrative expenses for the third quarter of 2018 were $1.273 million, compared with $1.556 million for the third quarter of 2017.

    The net loss from continuing operations for the third quarter of 2018 was $3.078 million, or $0.07 per share, compared with $1.252 million, or $0.04 per share, for the third quarter of 2017.

    Click here for the full press release.

    hemispherx biopharmanyse:heb
    The Conversation (0)

    Go Deeper

    AI Powered

    AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

    Bristol Myers Squibb Reports First Quarter Financial Results for 2023

    Bristol Myers Squibb Reports First Quarter Financial Results for 2023

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    Ă—